90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 26
- Registration Number
- NCT01247272
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 26
- Registration Number
- NCT01247285
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Anastrozole 1 mg Tablets Under Fed Conditions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT01183390
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2010-11-24
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 601
- Registration Number
- NCT01182636
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States
🇺🇸Academic Dermatology Associates, Albuquerque, New Mexico, United States
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT01182194
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 33
- Registration Number
- NCT01182207
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Anastrozole 1 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT01182181
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT01181726
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT01157169
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2010-12-17
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 36
- Registration Number
- NCT01157182
- Locations
- 🇨🇦
Biovail Clinical Research, Toronto, Ontario, Canada
© Copyright 2024. All Rights Reserved by MedPath